Drug intelligence / Profile preview

Risenex M

Development stage: Phase 4
Lead developer: Hanlim Pharm. Co., Ltd.
Modality: Small Molecules
Administration: Oral

Overview

Risenex M is a pharmaceutical drug developed by Hanlim Pharm Co.,Ltd. It is a combination medication primarily indicated for the prevention and treatment of osteoporosis in postmenopausal women. The drug is administered orally once a month and contains Risedronate, a third-generation bisphosphonate, and Vitamin D3. Risedronate works by inhibiting bone resorption through its action on osteoclasts, thereby increasing bone mineral density and reducing the risk of fractures. Vitamin D3 is essential for calcium absorption and bone health, playing a crucial role in bone mineralization.

Brand names: Risenex M

Targets

FDPS (Farnesyl pyrophosphate synthase)

Beyond the preview

Go deeper on Risenex M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Risenex M.

Explore the full profile